Restorgenex Corporation (RESX) 1.5000 $RESX
Diffusion Pharmaceuticals Announces Stock Ticker Symbol Change to DFFN
GlobeNewswire - Mon Jan 25, 6:30AM CST
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that FINRA has approved a change in the Company's stock symbol. Effective today, the Company's common shares will commence trading on the OTC Markets under the trading symbol "DFFN" (OTCQX
FFN). The previous trading symbol was "RESX" (OTCQX:RESX).
Diffusion Pharmaceuticals Announces Presentation at Biotech Showcase 2016
GlobeNewswire - Fri Jan 08, 3:08PM CST
Diffusion Pharmaceuticals, LLC (OTCQX:RESX), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that management will be presenting at Biotech Showcase 2016 to be held January 11 - 13, 2016 in San Francisco.
Diffusion Pharmaceuticals Completes Merger With RestorGenex and Becomes a Publicly Traded Oncology-Focused Biotechnology Company
GlobeNewswire - Fri Jan 08, 3:05PM CST
Diffusion Pharmaceuticals LLC, a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced the successful completion of its merger with RestorGenex Corporation (OTCQX:RESX). The combined company is changing its name to Diffusion Pharmaceuticals Inc.
The Life Sciences Report Announces the RestorGenex and Diffusion Pharmaceuticals Merger
Marketwired - Mon Dec 28, 8:00AM CST
The merger of RestorGenex Corp. (OTCQX: RESX) and privately held Diffusion Pharmaceuticals LLC, announced Tuesday, Dec. 15, will create an oncology-focused clinical-stage company with a diversified development portfolio of product candidates addressing novel targets, including several orphan indications, according to a press release issued by the companies. The combined company will be named Diffusion Pharmaceuticals Inc. and will be headquartered in Charlottesville, Virginia.
Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report
Marketwired - Fri Dec 04, 8:00AM CST
Why have stem cell and regenerative medicine companies underperformed other segments of biotech? Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer: Investors believe stem cell data has yet to definitively reach proof of concept in the blockbuster indications that the companies are pursuing. They want to see results like those shown by gene therapy/CAR-T companies, such as bluebird bio Inc. ("the Bird"
in sickle cell disease. In this interview with The Life Sciences Report, Kolbert and McCarthy tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives.
ATHX: 2.49 (+0.11), IMUC: 0.25 (+0.01), BCLI: 2.38 (-0.14)
RestorGenex Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 3:15PM CST
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported on its cash balance and financial results for the nine months ended September 30, 2015.
SeeThruEquity's Ajay Tandon and Jay Albany Interviewed by The Life Sciences Report
Marketwired - Thu Oct 29, 12:17PM CDT
SeeThruEquity's Ajay Tandon and Jay Albany are riding the biotech bull by harnessing the huge upside potential of micro-cap companies working in multiple subsectors, particularly in the rapidly advancing cancer immunotherapy sector. In this interview with The Life Sciences Report, Tandon and Albany toss the names of several companies into the arena for investors' consideration.
AEMD: 5.60 (+0.17)
RestorGenex to Present at Two Upcoming Growth Conferences
GlobeNewswire - Tue Oct 06, 6:00AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will provide a company overview at two upcoming growth conferences featuring biotechnology and pharmaceutical companies.
RestorGenex to Present at Rodman & Renshaw Global Investment Conference
GlobeNewswire - Thu Sep 03, 5:29AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. The conference will be held September 8-10, 2015 at the St. Regis Hotel in New York City.
RestorGenex Reports Financial Results
GlobeNewswire - Wed Aug 12, 5:30AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its cash balance and financial results for the six months ended June 30, 2015.
RestorGenex Announces Positive 3-D Cancer Cell Culture Data for RES-529, a TORC1/TORC2 Inhibitor
GlobeNewswire - Tue Jul 14, 5:30AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced positive data from a 3-D Cancer Cell Proliferation Assay with RES-529 and three analogs. The assay confirmed RES-529 activity for the lead indication of glioblastoma, while also demonstrating activity in several other oncology cell lines.
SeeThruEquity Initiates Coverage on RestorGenex Corp. with a Price Target of $8.93
ACCESSWIRE - Wed Jul 08, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / July 8, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of RestorGenex Corp. (OTCQX: RESX) with a price target of $8.93.
OTC Markets Group Welcomes RestorGenex to OTCQX
PR Newswire - Wed Jul 08, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced RestorGenex Corporation (OTCQX: RESX), a specialty biopharmaceutical company, has qualified to trade on the OTCQX® Best Marketplace.
RestorGenex Announces Presentation of Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor
GlobeNewswire - Fri Jun 19, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that in vitro and in vivo data will be presented on the use of RES-529 in a prostate cancer cell model. The data titled, "RES-529, A Dual TORC1/TORC2 Inhibitor, Potentiates the In Vitro and In Vivo Efficacy of Hormone Manipulations in the 22RV1 Prostate Cancer Cell Model" will be presented by Claudio Festuccia, Department of Clinical Sciences and Applied Biotechnology, Universita degli Studi dell'Aquila, at the XXVth National Congress of the Italian Society of Uro-Oncology (SIUrO), on June 22, 2015 in Rome, Italy.
RestorGenex Announces Stockholder Approval of Reincorporation in Delaware
GlobeNewswire - Thu Jun 18, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced today that stockholders in an annual meeting yesterday voted to reincorporate the company in Delaware effective promptly upon regulatory filings in Delaware and Nevada. The company intends to make these regulatory filings today, June 18, 2015. The company's common stock will continue to trade under the symbol "RESX".
RestorGenex CEO Featured in Equities.com Interview
GlobeNewswire - Tue Jun 16, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, was interviewed by Ed Kershen of Equities.com.
Restorgenex Corporation (RESX) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
GlobeNewswire - Thu Jun 04, 7:02AM CDT
Restorgenex Corporation (OTCMKTS:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.
RestorGenex to Present at the Annual LD Micro Invitational Conference
GlobeNewswire - Mon Jun 01, 5:30AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at the 5 Annual LD Micro Invitational Conference in Los Angeles, CA, on Tuesday, June 2, 2015 at 4:30 pm PT.
RestorGenex Announces Data on the Effect of RES-529 in Pulmonary Fibrosis Models
GlobeNewswire - Thu May 21, 5:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that Keith Ferguson, M.D. and Nathan Sandbo, M.D., both of the Division of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, presented scientific data utilizing RES-529 in idiopathic pulmonary fibrosis. The poster entitled "The Novel TOR Complex 1/2 Inhibitor RestorGenex 529 (RES-529) Inhibits Human Lung Myofibroblast Differentiation" was presented on Tuesday, May 19, 2015 at the American Thoracic Society International Conference in Denver, Colorado.
RestorGenex to Present at Two Investor Conferences
GlobeNewswire - Wed May 20, 3:00PM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at two upcoming investor conferences.
Diffusion Pharmaceuticals Announces Stock Ticker Symbol Change to DFFN
GlobeNewswire - Mon Jan 25, 6:30AM CST
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that FINRA has approved a change in the Company's stock symbol. Effective today, the Company's common shares will commence trading on the OTC Markets under the trading symbol "DFFN" (OTCQX
FFN). The previous trading symbol was "RESX" (OTCQX:RESX). Diffusion Pharmaceuticals Announces Presentation at Biotech Showcase 2016
GlobeNewswire - Fri Jan 08, 3:08PM CST
Diffusion Pharmaceuticals, LLC (OTCQX:RESX), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that management will be presenting at Biotech Showcase 2016 to be held January 11 - 13, 2016 in San Francisco.
Diffusion Pharmaceuticals Completes Merger With RestorGenex and Becomes a Publicly Traded Oncology-Focused Biotechnology Company
GlobeNewswire - Fri Jan 08, 3:05PM CST
Diffusion Pharmaceuticals LLC, a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced the successful completion of its merger with RestorGenex Corporation (OTCQX:RESX). The combined company is changing its name to Diffusion Pharmaceuticals Inc.
The Life Sciences Report Announces the RestorGenex and Diffusion Pharmaceuticals Merger
Marketwired - Mon Dec 28, 8:00AM CST
The merger of RestorGenex Corp. (OTCQX: RESX) and privately held Diffusion Pharmaceuticals LLC, announced Tuesday, Dec. 15, will create an oncology-focused clinical-stage company with a diversified development portfolio of product candidates addressing novel targets, including several orphan indications, according to a press release issued by the companies. The combined company will be named Diffusion Pharmaceuticals Inc. and will be headquartered in Charlottesville, Virginia.
Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report
Marketwired - Fri Dec 04, 8:00AM CST
Why have stem cell and regenerative medicine companies underperformed other segments of biotech? Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer: Investors believe stem cell data has yet to definitively reach proof of concept in the blockbuster indications that the companies are pursuing. They want to see results like those shown by gene therapy/CAR-T companies, such as bluebird bio Inc. ("the Bird"
in sickle cell disease. In this interview with The Life Sciences Report, Kolbert and McCarthy tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives. ATHX: 2.49 (+0.11), IMUC: 0.25 (+0.01), BCLI: 2.38 (-0.14)
RestorGenex Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 3:15PM CST
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported on its cash balance and financial results for the nine months ended September 30, 2015.
SeeThruEquity's Ajay Tandon and Jay Albany Interviewed by The Life Sciences Report
Marketwired - Thu Oct 29, 12:17PM CDT
SeeThruEquity's Ajay Tandon and Jay Albany are riding the biotech bull by harnessing the huge upside potential of micro-cap companies working in multiple subsectors, particularly in the rapidly advancing cancer immunotherapy sector. In this interview with The Life Sciences Report, Tandon and Albany toss the names of several companies into the arena for investors' consideration.
AEMD: 5.60 (+0.17)
RestorGenex to Present at Two Upcoming Growth Conferences
GlobeNewswire - Tue Oct 06, 6:00AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will provide a company overview at two upcoming growth conferences featuring biotechnology and pharmaceutical companies.
RestorGenex to Present at Rodman & Renshaw Global Investment Conference
GlobeNewswire - Thu Sep 03, 5:29AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. The conference will be held September 8-10, 2015 at the St. Regis Hotel in New York City.
RestorGenex Reports Financial Results
GlobeNewswire - Wed Aug 12, 5:30AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its cash balance and financial results for the six months ended June 30, 2015.
RestorGenex Announces Positive 3-D Cancer Cell Culture Data for RES-529, a TORC1/TORC2 Inhibitor
GlobeNewswire - Tue Jul 14, 5:30AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced positive data from a 3-D Cancer Cell Proliferation Assay with RES-529 and three analogs. The assay confirmed RES-529 activity for the lead indication of glioblastoma, while also demonstrating activity in several other oncology cell lines.
SeeThruEquity Initiates Coverage on RestorGenex Corp. with a Price Target of $8.93
ACCESSWIRE - Wed Jul 08, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / July 8, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of RestorGenex Corp. (OTCQX: RESX) with a price target of $8.93.
OTC Markets Group Welcomes RestorGenex to OTCQX
PR Newswire - Wed Jul 08, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced RestorGenex Corporation (OTCQX: RESX), a specialty biopharmaceutical company, has qualified to trade on the OTCQX® Best Marketplace.
RestorGenex Announces Presentation of Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor
GlobeNewswire - Fri Jun 19, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that in vitro and in vivo data will be presented on the use of RES-529 in a prostate cancer cell model. The data titled, "RES-529, A Dual TORC1/TORC2 Inhibitor, Potentiates the In Vitro and In Vivo Efficacy of Hormone Manipulations in the 22RV1 Prostate Cancer Cell Model" will be presented by Claudio Festuccia, Department of Clinical Sciences and Applied Biotechnology, Universita degli Studi dell'Aquila, at the XXVth National Congress of the Italian Society of Uro-Oncology (SIUrO), on June 22, 2015 in Rome, Italy.
RestorGenex Announces Stockholder Approval of Reincorporation in Delaware
GlobeNewswire - Thu Jun 18, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced today that stockholders in an annual meeting yesterday voted to reincorporate the company in Delaware effective promptly upon regulatory filings in Delaware and Nevada. The company intends to make these regulatory filings today, June 18, 2015. The company's common stock will continue to trade under the symbol "RESX".
RestorGenex CEO Featured in Equities.com Interview
GlobeNewswire - Tue Jun 16, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, was interviewed by Ed Kershen of Equities.com.
Restorgenex Corporation (RESX) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
GlobeNewswire - Thu Jun 04, 7:02AM CDT
Restorgenex Corporation (OTCMKTS:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.
RestorGenex to Present at the Annual LD Micro Invitational Conference
GlobeNewswire - Mon Jun 01, 5:30AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at the 5 Annual LD Micro Invitational Conference in Los Angeles, CA, on Tuesday, June 2, 2015 at 4:30 pm PT.
RestorGenex Announces Data on the Effect of RES-529 in Pulmonary Fibrosis Models
GlobeNewswire - Thu May 21, 5:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that Keith Ferguson, M.D. and Nathan Sandbo, M.D., both of the Division of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, presented scientific data utilizing RES-529 in idiopathic pulmonary fibrosis. The poster entitled "The Novel TOR Complex 1/2 Inhibitor RestorGenex 529 (RES-529) Inhibits Human Lung Myofibroblast Differentiation" was presented on Tuesday, May 19, 2015 at the American Thoracic Society International Conference in Denver, Colorado.
RestorGenex to Present at Two Investor Conferences
GlobeNewswire - Wed May 20, 3:00PM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at two upcoming investor conferences.
